$885 Million is the total value of Fairmount Funds Management LLC's 13 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | AXSOME THERAPEUTICS INC | $189,986,199 | +0.9% | 2,360,077 | 0.0% | 21.46% | +4.6% | |
| NUVALENT INC | $146,002,128 | +1.0% | 1,924,626 | 0.0% | 16.50% | +4.7% | ||
| Buy | SPYRE THERAPEUTICS INC | $94,465,555 | +558.1% | 4,018,101 | +961.8% | 10.67% | +582.0% | |
| APOGEE THERAPEUTICS INC | $80,614,259 | -40.8% | 2,048,647 | 0.0% | 9.11% | -38.6% | ||
| ENLIVEN THERAPEUTICS INC | $74,849,389 | +32.9% | 3,202,798 | 0.0% | 8.46% | +37.7% | ||
| DIANTHUS THERAPEUTICS INC | $71,502,222 | -13.7% | 2,762,837 | 0.0% | 8.08% | -10.6% | ||
| New | KINIKSA PHARMACEUTICALS INTL | $59,834,381 | – | 3,204,841 | +100.0% | 6.76% | – | |
| COGT | Buy | COGENT BIOSCIENCES INC | $52,482,154 | +65.3% | 6,225,641 | +31.7% | 5.93% | +71.3% |
| ASTRIA THERAPEUTICS INC | $32,342,574 | -35.3% | 3,554,129 | 0.0% | 3.65% | -33.0% | ||
| PTGX | PROTAGONIST THERAPEUTICS INC | $32,289,989 | +19.8% | 931,890 | 0.0% | 3.65% | +24.1% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $24,014,027 | -25.7% | 1,845,813 | 0.0% | 2.71% | -23.0% | |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $21,640,588 | – | 1,069,199 | +100.0% | 2.44% | – |
| TERN | Sell | TERNS PHARMACEUTICALS INC | $5,100,663 | -61.9% | 748,996 | -63.3% | 0.58% | -60.5% |
| GERN | Exit | GERON CORP | $0 | – | -6,666,667 | -100.0% | -2.40% | – |
| Exit | TYRA BIOSCIENCES INC | $0 | – | -1,393,329 | -100.0% | -2.49% | – | |
| MRUS | Exit | MERUS N V | $0 | – | -717,254 | -100.0% | -3.52% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -3,204,841 | -100.0% | -6.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AXSOME THERAPEUTICS INC | 18 | Q2 2024 | 24.6% |
| ARGENX SE | 17 | Q4 2023 | 9.3% |
| COGENT BIOSCIENCES INC | 15 | Q2 2024 | 7.2% |
| VIRIDIAN THERAPEUTICS INC | 14 | Q2 2024 | 6.3% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| NUVALENT INC | 12 | Q2 2024 | 17.1% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | June 13, 2024 | 11,330,141 | 9.9% |
| Spyre Therapeutics, Inc. | April 25, 2024 | 4,024,541 | 10.0% |
| Apogee Therapeutics, Inc. | April 01, 2024 | 4,762,558 | 10.0% |
| Dianthus Therapeutics, Inc. /DE/ | April 01, 2024 | 2,950,487 | 10.0% |
| Annexon, Inc. | February 14, 2024 | 322,893 | 0.4% |
| Astria Therapeutics, Inc. | February 14, 2024 | 3,633,965 | 9.9% |
| Axsome Therapeutics, Inc. | February 14, 2024 | 2,360,077 | 4.9% |
| Enliven Therapeutics, Inc. | February 14, 2024 | 2,131,369 | 5.2% |
| Kiniksa Pharmaceuticals, Ltd. | February 14, 2024 | 2,883,221 | 8.1% |
| Nuvalent, Inc. | February 14, 2024 | 1,924,626 | 3.4% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-10-17 |
| 4 | 2024-10-01 |
| 4/A | 2024-09-17 |
| 4 | 2024-09-17 |
| SC 13D/A | 2024-09-17 |
| 4 | 2024-09-16 |
| 4 | 2024-09-13 |
| SC 13D/A | 2024-09-13 |
| 3 | 2024-09-12 |
| 3 | 2024-09-06 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.